8-K: Motus GI Holdings Faces Nasdaq Delisting After Share Price Fails to Meet Minimum Bid Requirement

Motus GI Holdings is set to be delisted from the Nasdaq Capital Market after its share price remained below $1 for 30 consecutive days, and will move to the OTC Pink Market.

Summary

• Motus GI Holdings received a notification from Nasdaq stating that its common stock price had fallen below $1 for 30 consecutive business days, violating listing rules.
• Due to previous reverse stock splits, the company is not eligible for a compliance period to regain listing.
• The company does not intend to appeal the delisting decision and expects trading on Nasdaq to be suspended on April 16, 2024.
• The stock will then be quoted on the OTC Pink Market, and the company plans to apply for listing on the OTCQB.
• Motus GI is exploring strategic and financing options to maximize shareholder value and commercialize its Pure-Vu System.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting from Nasdaq, which is a significant setback for the company. However, the company is exploring strategic alternatives, which provides a small glimmer of hope.

Positives

• The company is actively exploring strategic and financing alternatives.
• Motus GI plans to apply for listing on the OTCQB market.

Negatives

• The company's stock price has fallen below the minimum bid price requirement of $1 for 30 consecutive days.
• Motus GI is being delisted from the Nasdaq Capital Market.
• The company is not eligible for a compliance period due to previous reverse stock splits.

Risks

• The company faces the risk of delisting from Nasdaq.
• There is a risk that the company may not meet the listing standards for the OTCQB.
• The company's ability to raise capital and execute its strategic plans may be impacted by the delisting.

Future Outlook

The company intends to list on the OTCQB and is exploring strategic and financing alternatives to maximize stockholder value and accelerate the commercialization of the Pure-Vu System.

Management Comments

• The company does not intend to appeal the Staff's determination.
• The company is continuing to explore a range of strategic and financing alternatives focused on maximizing stockholder value and accelerating the commercialization of the Pure-Vu System.

Industry Context

This delisting highlights the challenges faced by smaller companies in maintaining Nasdaq listing requirements, particularly those with volatile stock prices. It is not uncommon for companies to move to the OTC markets after failing to meet Nasdaq's minimum bid price rule.

Comparison to Industry Standards

• Many small-cap biotech companies face similar challenges in maintaining Nasdaq listing compliance, especially those with pre-revenue products.
• Companies like Motus GI often rely on capital raises and strategic partnerships to fund operations and commercialization efforts, and a delisting can make these more difficult.
• The move to the OTC markets is a common path for companies that fail to meet Nasdaq's listing requirements, with the hope of eventually relisting on a major exchange.

Stakeholder Impact

• Shareholders will likely experience a negative impact due to the delisting and potential decrease in stock value.
• The company's ability to raise capital may be affected, potentially impacting future growth and operations.
• Employees may experience uncertainty due to the company's financial challenges.

Next Steps

• The company will move to the OTC Pink Market.
• The company plans to apply for listing on the OTCQB.
• The company will continue to explore strategic and financing alternatives.

Key Dates

Keywords

delisting, Nasdaq, stock price, OTC Pink Market, OTCQB, reverse stock split, listing rule, strategic alternatives, financing, Pure-Vu System